

Charles Adler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2895550/publications.pdf>

Version: 2024-02-01

193
papers

21,868
citations

17405

63
h-index

10127

140
g-index

199
all docs

199
docs citations

199
times ranked

16738
citing authors

#	ARTICLE	IF	CITATIONS
1	An initial exploration of the convergent and ecological validity of the UDS 3.0 neuropsychological battery in Parkinson's Disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2022, , 1-8.	0.8	3
2	Antemortem detection of Parkinson's disease pathology in peripheral biopsies using artificial intelligence. <i>Acta Neuropathologica Communications</i> , 2022, 10, 21.	2.4	8
3	Level I <sc>PD</sc> Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 479-483.	0.8	11
4	Synuclein-One study: skin biopsy detection of phosphorylated α -synuclein for diagnosis of synucleinopathies. <i>Biomarkers in Medicine</i> , 2022, 16, 499-509.	0.6	8
5	Effect of olfactory bulb pathology on olfactory function in normal aging. <i>Brain Pathology</i> , 2022, 32, e13075.	2.1	13
6	Performance of α -Synuclein RT-QuIC in relation to neuropathological staging of Lewy body disease. <i>Acta Neuropathologica Communications</i> , 2022, 10, .	2.4	31
7	Olfactory Bulb Amyloid- β^2 Correlates With Brain Thal Amyloid Phase and Severity of Cognitive Impairment. <i>Journal of Neuropathology and Experimental Neurology</i> , 2022, 81, 643-649.	0.9	4
8	SARS-CoV-2 Brain Regional Detection, Histopathology, Gene Expression, and Immunomodulatory Changes in Decedents with COVID-19. <i>Journal of Neuropathology and Experimental Neurology</i> , 2022, 81, 666-695.	0.9	22
9	Dystonia and Tremor. <i>Neurology</i> , 2021, 96, e563-e574.	1.5	46
10	Essential tremor and cognitive decline. <i>Parkinsonism and Related Disorders</i> , 2021, 83, 125.	1.1	3
11	National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome. <i>Neurology</i> , 2021, 96, 848-863.	1.5	149
12	Olfaction in Neuropathologically Defined Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2021, 36, 1700-1704.	2.2	7
13	Clinicopathological Correlation: Dopamine and Amyloid PET Imaging with Neuropathology in Three Subjects Clinically Diagnosed with Alzheimer's Disease or Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 1603-1612.	1.2	2
14	α -Synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinson's disease from multiple system atrophy. <i>Acta Neuropathologica</i> , 2021, 142, 495-511.	3.9	80
15	Restless Legs Syndrome Shows Increased Silent Postmortem Cerebral Microvascular Disease With Gliosis. <i>Journal of the American Heart Association</i> , 2021, 10, e019627.	1.6	7
16	Vagus Nerve and Stomach Synucleinopathy in Parkinson's Disease, Incidental Lewy Body Disease, and Normal Elderly Subjects: Evidence Against the "œBody-First" Hypothesis. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1833-1843.	1.5	41
17	Non-motor phenotypic subgroups in adult-onset idiopathic, isolated, focal cervical dystonia. <i>Brain and Behavior</i> , 2021, 11, e2292.	1.0	11
18	Biomarkers of conversion to α -synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder. <i>Lancet Neurology</i> , The, 2021, 20, 671-684.	4.9	116

#	ARTICLE	IF	CITATIONS
19	Predictive modeling of spread in adult-onset isolated dystonia: Key properties and effect of tremor inclusion. <i>European Journal of Neurology</i> , 2021, 28, 3999-4009.	1.7	2
20	Developing methods to detect and diagnose chronic traumatic encephalopathy during life: rationale, design, and methodology for the DIAGNOSE CTE Research Project. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 136.	3.0	30
21	Clinical Diagnostic Accuracy of Early/Advanced Parkinson Disease: An Updated Clinicopathologic Study. <i>Neurology: Clinical Practice</i> , 2021, 11, e414-e421.	0.8	1
22	Disease Duration Influences Gene Expression in Neuromelanin-Positive Cells From Parkinson's Disease Patients. <i>Frontiers in Molecular Neuroscience</i> , 2021, 14, 763777.	1.4	9
23	Clinical Diagnostic Accuracy of Early/Advanced Parkinson Disease. <i>Neurology: Clinical Practice</i> , 2021, 11, e414-e421.	0.8	16
24	Dystonic Golfer's cramp: Pilot study of propranolol and looking at the hole. <i>Parkinsonism and Related Disorders</i> , 2020, 80, 108-112.	1.1	3
25	In vivo distribution of α -synuclein in multiple tissues and biofluids in Parkinson disease. <i>Neurology</i> , 2020, 95, e1267-e1284.	1.5	91
26	Dopaminergic Retinal Cell Loss and Visual Dysfunction in Parkinson Disease. <i>Annals of Neurology</i> , 2020, 88, 893-906.	2.8	52
27	Association of probable REM sleep behavior disorder with pathology and years of contact sports play in chronic traumatic encephalopathy. <i>Acta Neuropathologica</i> , 2020, 140, 851-862.	3.9	19
28	Blinded RT-QuIC Analysis of α -Synuclein Biomarker in Skin Tissue From Parkinson's Disease Patients. <i>Movement Disorders</i> , 2020, 35, 2230-2239.	2.2	88
29	Neuropathological Findings in Parkinson's Disease With Mild Cognitive Impairment. <i>Movement Disorders</i> , 2020, 35, 845-850.	2.2	14
30	Cardiac sympathetic denervation and synucleinopathy in Alzheimer's disease with brain Lewy body disease. <i>Brain Communications</i> , 2020, 2, fcaa004.	1.5	7
31	Do Parkinson disease subject and caregiver-reported Epworth sleepiness scale responses correlate?. <i>Clinical Neurology and Neurosurgery</i> , 2020, 192, 105728.	0.6	2
32	Co-Existence of tau and α -synuclein pathology in fetal graft tissue at autopsy: A case report. <i>Parkinsonism and Related Disorders</i> , 2020, 71, 36-39.	1.1	11
33	Severe hyposmia distinguishes neuropathologically confirmed dementia with Lewy bodies from Alzheimer's disease dementia. <i>PLoS ONE</i> , 2020, 15, e0231720.	1.1	27
34	It's tricky: Rating alleviating maneuvers in cervical dystonia. <i>Journal of the Neurological Sciences</i> , 2020, 419, 117205.	0.3	6
35	Contrast Acuity With Different Colors in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 672-677.	0.8	6
36	Brain Lewy-Type Synucleinopathy Density Is Associated with a Lower Prevalence of Atherosclerotic Cardiovascular Disease Risk Factors in Patients with Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2019, 9, 543-552.	1.5	3

#	ARTICLE	IF	CITATIONS
37	Feasibility of repeat and bilateral submandibular gland needle biopsies in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 68, 69-72.	1.1	14
38	Unified Staging System for Lewy Body Disorders: Clinicopathologic Correlations and Comparison to Braak Staging. <i>Journal of Neuro pathology and Experimental Neurology</i> , 2019, 78, 891-899.	0.9	44
39	Minimal clinically important change in patients with cervical dystonia: Results from the CD PROBE study. <i>Journal of the Neurological Sciences</i> , 2019, 405, 116413.	0.3	14
40	Regional neuropathology distribution and verbal fluency impairments in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 73-78.	1.1	12
41	Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease. <i>PLoS ONE</i> , 2019, 14, e0217566.	1.1	31
42	Tau Positron-Emission Tomography in Former National Football League Players. <i>New England Journal of Medicine</i> , 2019, 380, 1716-1725.	13.9	165
43	Lewy body pathology in Alzheimer's disease: A clinicopathological prospective study. <i>Acta Neurologica Scandinavica</i> , 2019, 139, 76-81.	1.0	32
44	Tau immunoreactivity in peripheral tissues of human aging and select tauopathies. <i>Neuroscience Letters</i> , 2019, 696, 132-139.	1.0	33
45	Risk of Parkinson's disease dementia related to level I MDS PDâ€MCI. <i>Movement Disorders</i> , 2019, 34, 430-435.	2.2	32
46	Correlation Between the Movement Disorder Society's Unified Parkinson's Disease Rating Scale and Nonmotor Scales in Patients with Parkinson's Disease. <i>Innovations in Clinical Neuroscience</i> , 2019, 16, 27-29.	0.1	2
47	Probing the striatal dopamine system for a putative neuroprotective effect of deep brain stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 652-654.	2.2	5
48	Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Openâ€label ADSâ€102. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 183-190.	0.8	15
49	Are Clinical Certainty Ratings Helpful in the Diagnosis of Parkinson's Disease?. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 165-170.	0.8	1
50	Association Between Pathology and Electroencephalographic Activity in Parkinsonâ€™s Disease. <i>Clinical EEG and Neuroscience</i> , 2018, 49, 321-327.	0.9	5
51	Does Parkinsonâ€™s disease start in the gut?. <i>Acta Neuropathologica</i> , 2018, 135, 1-12.	3.9	161
52	Guidance for switching from off-label antipsychotics to pimavanserin for Parkinsonâ€™s disease psychosis: an expert consensus. <i>CNS Spectrums</i> , 2018, 23, 402-413.	0.7	8
53	Importance of low diagnostic Accuracy for early Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1551-1554.	2.2	70
54	Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for Î±-Synuclein in Parkinsonâ€™s Disease: The Systemic Synuclein Sampling Study (S4). <i>Journal of Parkinson's Disease</i> , 2018, 8, 517-527.	1.5	16

#	ARTICLE	IF	CITATIONS
55	Enhancers active in dopamine neurons are a primary link between genetic variation and neuropsychiatric disease. <i>Nature Neuroscience</i> , 2018, 21, 1482-1492.	7.1	79
56	Degeneration of human photosensitive retinal ganglion cells may explain sleep and circadian rhythms disorders in Parkinson's disease. <i>Acta Neuropathologica Communications</i> , 2018, 6, 90.	2.4	56
57	Characterization of the symptoms of neurogenic orthostatic hypotension and their impact from a survey of patients and caregivers. <i>BMC Neurology</i> , 2018, 18, 125.	0.8	39
58	Predicting alpha-synuclein pathology by REM sleep behavior disorder diagnosis. <i>Parkinsonism and Related Disorders</i> , 2018, 55, 92-96.	1.1	19
59	Consensus-Based Attributes for Identifying Patients With Spasmodic Dysphonia and Other Voice Disorders. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2018, 144, 657.	1.2	47
60	Phosphorylated α -synuclein in the retina is a biomarker of Parkinson's disease pathology severity. <i>Movement Disorders</i> , 2018, 33, 1315-1324.	2.2	113
61	Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4). <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 793-802.	0.9	32
62	Movement disorder society criteria for clinically established early Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1643-1646.	2.2	114
63	The Yips: Methods to Identify Golfers with a Dystonic Etiology/Golfer's Cramp. <i>Medicine and Science in Sports and Exercise</i> , 2018, 50, 2226-2230.	0.2	21
64	Weight Loss in Parkinson's Disease: No Evidence for Role of Small Intestinal Bacterial Overgrowth. <i>Journal of Parkinson's Disease</i> , 2018, 8, 571-581.	1.5	17
65	The Search for a Peripheral Biopsy Indicator of α -Synuclein Pathology for Parkinson Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, n1w103.	0.9	73
66	The Systemic Synuclein Sampling Study: toward a biomarker for Parkinson's disease. <i>Biomarkers in Medicine</i> , 2017, 11, 359-368.	0.6	50
67	Comparison of neuropathology in Parkinson's disease subjects with and without deep brain stimulation. <i>Movement Disorders</i> , 2017, 32, 274-277.	2.2	20
68	Mild cognitive impairment as a risk factor for Parkinson's disease dementia. <i>Movement Disorders</i> , 2017, 32, 1056-1065.	2.2	117
69	Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimer's pathology not α -synuclein pathology. <i>Neurobiology of Aging</i> , 2017, 54, 175-186.	1.5	26
70	Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry. <i>Journal of the Neurological Sciences</i> , 2017, 376, 84-90.	0.3	30
71	The association between vertebrobasilar dolichoectasia and hemifacial spasm: Historical perspective. <i>Parkinsonism and Related Disorders</i> , 2017, 38, 97.	1.1	0
72	Improved diagnosis of Parkinson's disease from a detailed olfactory phenotype. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 714-721.	1.7	12

#	ARTICLE	IF	CITATIONS
73	Spasmodic Dysphonia: A Review. Part 2: Characterization of Pathophysiology. Otolaryngology - Head and Neck Surgery, 2017, 157, 558-564.	1.1	38
74	Spasmodic Dysphonia: A Review. Part 1: Pathogenic Factors. Otolaryngology - Head and Neck Surgery, 2017, 157, 551-557.	1.1	43
75	GBA mutations in Parkinson disease: earlier death but similar neuropathological features. European Journal of Neurology, 2017, 24, 1363-1368.	1.7	27
76	Hypermethylation of Synphilin-1, Alpha-Synuclein-Interacting Protein (SNCAIP) Gene in the Cerebral Cortex of Patients with Sporadic Parkinson's Disease. Brain Sciences, 2017, 7, 74.	1.1	9
77	The science of the yips. , 2017, , 369-379.		0
78	Differential spectral quantitative electroencephalography patterns between control and Parkinson's disease cohorts. European Journal of Neurology, 2016, 23, 387-392.	1.7	40
79	Peripheral <i>Synucleinopathy</i> in <i>Early Parkinson's Disease</i> : <i>Submandibular Gland Needle Biopsy Findings</i> . Movement Disorders, 2016, 31, 250-256.	2.2	66
80	Cortical phosphorylated β -Synuclein levels correlate with brain wave spectra in Parkinson's disease. Movement Disorders, 2016, 31, 1012-1019.	2.2	27
81	Neuropathological basis of nonmotor manifestations of Parkinson's disease. Movement Disorders, 2016, 31, 1114-1119.	2.2	173
82	Prevalence of Submandibular Gland Synucleinopathy in Parkinson's Disease, Dementia with Lewy Bodies and other Lewy Body Disorders. Journal of Parkinson's Disease, 2016, 6, 153-163.	1.5	58
83	Multicenter Assessment of Immunohistochemical Methods for Pathological Alpha-Synuclein in Sigmoid Colon of Autopsied Parkinson's Disease and Control Subjects. Journal of Parkinson's Disease, 2016, 6, 761-770.	1.5	68
84	The new definition and diagnostic criteria of Parkinson's disease. Lancet Neurology, The, 2016, 15, 546-548.	4.9	82
85	Abolishing the 1-year rule: How much evidence will be enough?. Movement Disorders, 2016, 31, 1623-1627.	2.2	43
86	Knowledge gaps and research recommendations for essential tremor. Parkinsonism and Related Disorders, 2016, 33, 27-35.	1.1	46
87	Unawareness of Hyposmia in Elderly People With and Without Parkinson's Disease. Movement Disorders Clinical Practice, 2016, 3, 43-47.	0.8	12
88	Impact of Cervical Dystonia on Work Productivity: An Analysis From a Patient Registry. Movement Disorders Clinical Practice, 2016, 3, 130-138.	0.8	31
89	Gender Differences in Alzheimer Disease: Brain Atrophy, Histopathology Burden, and Cognition. Journal of Neuropathology and Experimental Neurology, 2016, 75, 748-754.	0.9	82
90	Next-generation profiling to identify the molecular etiology of Parkinson dementia. Neurology: Genetics, 2016, 2, e75.	0.9	25

#	ARTICLE	IF	CITATIONS
91	Assessing medication role on neuropathological findings in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 613-614.	2.2	0
92	Lewy bodies are incidental in essential tremor. <i>Parkinsonism and Related Disorders</i> , 2016, 26, 81.	1.1	2
93	Graph theory network function in Parkinson's disease assessed with electroencephalography. <i>Clinical Neurophysiology</i> , 2016, 127, 2228-2236.	0.7	79
94	Pathological α -synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology. <i>Acta Neuropathologica</i> , 2016, 131, 393-409.	3.9	123
95	Advances in Biomarker Research in Parkinson's Disease. <i>Current Neurology and Neuroscience Reports</i> , 2016, 16, 7.	2.0	37
96	Lewy bodies in essential tremor are no different than in controls. <i>Parkinsonism and Related Disorders</i> , 2016, 23, 106-107.	1.1	6
97	MDS research criteria for prodromal Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1600-1611.	2.2	1,033
98	Abnormal Visual Contrast Acuity in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 125-130.	1.5	33
99	Clinical Features of Patients with Concomitant Parkinson's Disease and Progressive Supranuclear Palsy Pathology. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 33-38.	0.8	1
100	Simplified conversion method for unified Parkinson's disease rating scale motor examinations. <i>Movement Disorders</i> , 2015, 30, 1967-1970.	2.2	59
101	The Mayo Clinic Arizona Spasmodic Dysphonia Experience. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 2015, 124, 859-863.	0.6	45
102	A study of aging and neurodegenerative disorders and brain and body donation program. <i>Neuropathology</i> , 2015, 35, 354-389.	0.7	336
103	MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1591-1601.	2.2	4,389
104	Primary results from the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE). <i>Journal of the Neurological Sciences</i> , 2015, 349, 84-93.	0.3	67
105	Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinson's Disease Patients. <i>Dysphagia</i> , 2015, 30, 404-417.	1.0	36
106	Parkinson disease and incidental Lewy body disease. <i>Neurology</i> , 2015, 85, 1670-1679.	1.5	88
107	Neuropathological comparisons of amnesic and nonamnesic mild cognitive impairment. <i>BMC Neurology</i> , 2015, 15, 146.	0.8	36
108	REM sleep behavior disorder and neuropathology in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1413-1417.	2.2	128

#	ARTICLE	IF	CITATIONS
109	Role for the microtubule-associated protein tau variant p.A152T in risk of α -synucleinopathies. <i>Neurology</i> , 2015, 85, 1680-1686.	1.5	31
110	Essential Tremor in the Elderly and Risk for Dementia. <i>Journal of Neurodegenerative Diseases</i> , 2014, 2014, 1-5.	1.1	17
111	Clinicopathological Outcomes of Prospectively Followed Normal Elderly Brain Bank Volunteers. <i>Journal of Neuropathology and Experimental Neurology</i> , 2014, 73, 244-252.	0.9	65
112	A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 543.	4.5	312
113	Concomitant pathologies among a spectrum of parkinsonian disorders. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 525-529.	1.1	107
114	The neurobiological basis of cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 634-650.	2.2	282
115	Slowing of number naming speed by King's Devick Test in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 226-229.	1.1	30
116	Olfactory dysfunction in incidental Lewy body disease and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1260-1262.	1.1	68
117	Submandibular gland needle biopsy for the diagnosis of Parkinson disease. <i>Neurology</i> , 2014, 82, 858-864.	1.5	120
118	Low clinical diagnostic accuracy of early vs advanced Parkinson disease. <i>Neurology</i> , 2014, 83, 406-412.	1.5	395
119	Phosphorylated α -synuclein-immunoreactive retinal neuronal elements in Parkinson's disease subjects. <i>Neuroscience Letters</i> , 2014, 571, 34-38.	1.0	115
120	Quantitative Measurement of Intact Alpha-Synuclein Proteoforms from Post-Mortem Control and Parkinson's Disease Brain Tissue by Intact Protein Mass Spectrometry. <i>Scientific Reports</i> , 2014, 4, 5797.	1.6	133
121	Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. <i>Brain</i> , 2013, 136, 2419-2431.	3.7	965
122	Changes in properties of serine 129 phosphorylated α -synuclein with progression of Lewy-type histopathology in human brains. <i>Experimental Neurology</i> , 2013, 240, 190-204.	2.0	120
123	Quantitative Appraisal of Ventricular Cerebrospinal Fluid Biomarkers in Neuropathologically Diagnosed Parkinson's Disease Cases Lacking Alzheimer's Disease Pathology. <i>Biomarker Insights</i> , 2013, 8, BMS11422.	1.0	13
124	Alpha-Synuclein Pathology and Axonal Degeneration of the Peripheral Motor Nerves Innervating Pharyngeal Muscles in Parkinson Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013, 72, 119-129.	0.9	112
125	Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013, 72, 130-136.	0.9	106
126	Parkinson Disease Affects Peripheral Sensory Nerves in the Pharynx. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013, 72, 614-623.	0.9	123

#	ARTICLE	IF	CITATIONS
127	Prevalence of hippocampal sclerosis in a clinicopathologically characterized cohort. <i>Clinical and Experimental Medical Sciences</i> , 2013, 1, 317-327.	0.4	7
128	Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects. <i>Neurological Research</i> , 2012, 34, 669-676.	0.6	57
129	Altered Pharyngeal Muscles in Parkinson Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2012, 71, 520-530.	0.9	118
130	Presence of Striatal Amyloid Plaques in Parkinson's Disease Dementia Predicts Concomitant Alzheimer's Disease: Usefulness for Amyloid Imaging. <i>Journal of Parkinson's Disease</i> , 2012, 2, 57-65.	1.5	38
131	Movement Disorders and Sleep. <i>Neurologic Clinics</i> , 2012, 30, 1345-1358.	0.8	9
132	Pathology in essential tremor. <i>Parkinsonism and Related Disorders</i> , 2012, 18, S135-S137.	1.1	29
133	Parkinson's disease is not associated with gastrointestinal myenteric ganglion neuron loss. <i>Acta Neuropathologica</i> , 2012, 124, 665-680.	3.9	169
134	Biochemical Increase in Phosphorylated Alpha-Synuclein Precedes Histopathology of Lewy-Type Synucleinopathies. <i>Brain Pathology</i> , 2012, 22, 745-756.	2.1	62
135	Autonomic function, as self-reported on the SCOPA-autonomic questionnaire, is normal in essential tremor but not in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 1089-1093.	1.1	54
136	Essential tremor is not a neurodegenerative disease. <i>Neurodegenerative Disease Management</i> , 2012, 2, 259-268.	1.2	47
137	Brain biochemistry in autopsied patients with essential tremor. <i>Movement Disorders</i> , 2012, 27, 113-117.	2.2	48
138	Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. <i>Movement Disorders</i> , 2012, 27, 349-356.	2.2	1,908
139	Sports-related task-specific dystonia: The yips. , 2012, , 212-220.		0
140	Premotor Symptoms and Early Diagnosis of Parkinson's Disease. <i>International Journal of Neuroscience</i> , 2011, 121, 3-8.	0.8	20
141	Incidental Lewy body disease: Electrophysiological findings suggesting pre-clinical Lewy body disorders. <i>Clinical Neurophysiology</i> , 2011, 122, 2426-2432.	0.7	10
142	Neuropathological findings of PSP in the elderly without clinical PSP: Possible incidental PSP?. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 365-371.	1.1	43
143	Probable RBD is increased in Parkinson's disease but not in essential tremor or restless legs syndrome. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 456-458.	1.1	73
144	Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE). <i>BMC Neurology</i> , 2011, 11, 140.	0.8	25

#	ARTICLE	IF	CITATIONS
145	Essential tremor and Parkinson's disease: Lack of a link. <i>Movement Disorders</i> , 2011, 26, 372-377.	2.2	53
146	Parkinson's disease, cortical dysfunction, and alpha-synuclein. <i>Movement Disorders</i> , 2011, 26, 1436-1442.	2.2	16
147	MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD-MCI. <i>Movement Disorders</i> , 2011, 26, 1814-1824.	2.2	649
148	Are the yips a task-specific dystonia or "golfer's cramp"? <i>Movement Disorders</i> , 2011, 26, 1993-1996.	2.2	34
149	Quantitative EEG as a predictive biomarker for Parkinson disease dementia. <i>Neurology</i> , 2011, 77, 118-124.	1.5	178
150	The Montreal Cognitive Assessment and the Mini-Mental State Examination as Screening Instruments for Cognitive Impairment: Item Analyses and Threshold Scores. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 31, 126-131.	0.7	200
151	Are there differences in cerebral white matter lesion burdens between Parkinson's disease patients with or without dementia?. <i>Acta Neuropathologica</i> , 2010, 119, 147-149.	3.9	40
152	Multi-organ distribution of phosphorylated α -synuclein histopathology in subjects with Lewy body disorders. <i>Acta Neuropathologica</i> , 2010, 119, 689-702.	3.9	758
153	Heterogeneous neuropathological findings in Parkinson's disease with mild cognitive impairment. <i>Acta Neuropathologica</i> , 2010, 120, 827-828.	3.9	75
154	Variability of diffuse plaques and amyloid angiopathy in Parkinson's disease with mild cognitive impairment. <i>Acta Neuropathologica</i> , 2010, 120, 831-831.	3.9	6
155	An Update on the Neurologic Applications of Botulinum Toxins. <i>Current Neurology and Neuroscience Reports</i> , 2010, 10, 338-344.	2.0	27
156	Incidental Lewy body disease: Clinical comparison to a control cohort. <i>Movement Disorders</i> , 2010, 25, 642-646.	2.2	109
157	Olfaction in the Elderly: A Cross-Sectional Analysis Comparing Parkinson's Disease with Controls and Other Disorders. <i>International Journal of Neuroscience</i> , 2010, 120, 36-39.	0.8	43
158	Olfactory bulb α -synucleinopathy has high specificity and sensitivity for Lewy body disorders. <i>Acta Neuropathologica</i> , 2009, 117, 169-74.	3.9	193
159	Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. <i>Acta Neuropathologica</i> , 2009, 117, 613-634.	3.9	553
160	Perioperative use of botulinum toxins. <i>Toxicon</i> , 2009, 54, 654-657.	0.8	5
161	Mild cognitive impairment in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S81-S82.	1.1	1
162	Parkinson Disease With Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2009, 23, 295-297.	0.6	183

#	ARTICLE	IF	CITATIONS
163	Correlation of Clinical Features With Argyrophilic Grains at Autopsy. <i>Alzheimer Disease and Associated Disorders</i> , 2009, 23, 229-233.	0.6	35
164	Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. <i>Acta Neuropathologica</i> , 2008, 115, 445-451.	3.9	116
165	Evaluation of α -synuclein immunohistochemical methods used by invited experts. <i>Acta Neuropathologica</i> , 2008, 116, 277-288.	3.9	157
166	Pathologic findings in prospectively ascertained essential tremor subjects. <i>Neurology</i> , 2008, 70, 1452-1455.	1.5	191
167	High specificity and sensitivity of olfactory bulb synucleinopathy for Lewy body disorders. <i>FASEB Journal</i> , 2008, 22, 58.8.	0.2	0
168	Both early and late cognitive dysfunction affects the electroencephalogram in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 348-354.	1.1	110
169	Defining mild cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1272-1277.	2.2	388
170	The patient with Parkinson's disease: Part I?Treating the motor symptoms; Part II?Treating the nonmotor symptoms. <i>Journal of the American Academy of Nurse Practitioners</i> , 2007, 19, 179-197.	1.4	23
171	Sports-Related Task-Specific Dystonia: The Yips. <i>Medical Psychiatry</i> , 2006, , 209-217.	0.2	1
172	Nonmotor complications in Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, S23-S29.	2.2	140
173	Abnormal co-contraction in yips-affected but not unaffected golfers: Evidence for focal dystonia. <i>Neurology</i> , 2005, 64, 1813-1814.	1.5	71
174	Parkinson's Disease and Sleep. <i>Neurologic Clinics</i> , 2005, 23, 1187-1208.	0.8	43
175	Sleep issues in Parkinson's disease. <i>Neurology</i> , 2005, 64, S12-20.	1.5	121
176	Botulinum Toxin Type A for Treating Voice Tremor. <i>Archives of Neurology</i> , 2004, 61, 1416.	4.9	91
177	Ropinirole for restless legs syndrome. <i>Neurology</i> , 2004, 62, 1405-1407.	1.5	98
178	Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia. <i>Movement Disorders</i> , 2004, 19, 1075-1079.	2.2	37
179	Cerebellar ataxia, dystonia, and tremor within a family: Variable phenotypes of a single genetic disorder?. <i>Movement Disorders</i> , 2004, 9, 155-160.	2.2	6
180	Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. <i>Movement Disorders</i> , 2003, 18, 287-293.	2.2	265

#	ARTICLE	IF	CITATIONS
181	The ???Yips??? in Golf. Sports Medicine, 2003, 33, 13-31.	3.1	80
182	Motor impairment in normal aging, clinically possible Parkinson's disease, and clinically probable Parkinson's disease: longitudinal evaluation of a cohort of prospective brain donors. Parkinsonism and Related Disorders, 2002, 9, 103-110.	1.1	36
183	Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia. Movement Disorders, 2002, 17, 158-161.	2.2	18
184	Relevance of motor complications in Parkinsonâ€™s disease. Neurology, 2002, 58, S51-6.	1.5	38
185	A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology, 2001, 56, 1523-1528.	1.5	207
186	Strategies for controlling dystonia. Postgraduate Medicine, 2000, 108, 151-160.	0.9	16
187	Electrophysiological observations in hereditary parkinsonism-dementia with Lewy body pathology. Movement Disorders, 2000, 15, 140-145.	2.2	19
188	Lexical boundary error analysis in hypokinetic and ataxic dysarthria. Journal of the Acoustical Society of America, 2000, 107, 3415-3424.	0.5	56
189	Safety and efficacy of NeuroBloc (botulinum toxin type B) in type Aâ€™resistant cervical dystonia. Neurology, 1999, 53, 1431-1431.	1.5	427
190	DIFFERENTIAL DIAGNOSIS OF PARKINSON'S DISEASE. Medical Clinics of North America, 1999, 83, 349-367.	1.1	18
191	Syllabic strength and lexical boundary decisions in the perception of hypokinetic dysarthric speech. Journal of the Acoustical Society of America, 1998, 104, 2457-2466.	0.5	84
192	Perioperative use of botulinum toxin for movement disorder-induced cervical spine disease. Movement Disorders, 1996, 11, 79-81.	2.2	60
193	Hemifacial spasm: Evaluation by magnetic resonance imaging and magnetic resonance tomographic angiography. Annals of Neurology, 1992, 32, 502-506.	2.8	99